Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

190articles mentioning diseases

354disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: Solid Tumors ×

Solid Tumors

This disease is selected. Its supporting articles are shown below.

Solid Tumors190

Articles mentioning Solid Tumors

190 articles · page 5 of 16

1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study

jitc · abstract · 2025-11-07 · 2 matching annotations

92.3%

cSCC solid tumors melanoma pembrolizumab

…ars-of-age with histologically confirmed stage II–IV resectable cSCC (without M1; head/neck tumor staging per AJCC 8th ed; other tum…

1324 Innovative phase II clinical trial of gut microbiota targeting therapeutics to overcome acquired resistance to immune checkpoint inhibitors in solid tumors

jitc · abstract · 2025-11-07 · 2 matching annotations

77.6%

advanced solid tumors gastric cancer esophageal cancer solid tumors Showa Medical University

…bitors (ICIs) remains an urgent unmet need in the management of advanced solid tumors. ICI retreatment has demonstrated minimal clinical benefit. Acc…

1040 Racial differences in peripheral cytokine signature do not lead to differences in immunotherapy outcome or toxicity

jitc · abstract · 2025-11-04 · 2 matching annotations

86.7%

solid tumors advanced/metastatic disease Johns Hopkins IRB #00267960

…lled patients receiving standard-of-care ICI-based regimens for solid tumors at Johns Hopkins (IRB #00267960) and performed analysis of 39 c…

1055 Flat toxicity curve across PD-1/PD-L1 inhibitor dose densities: meta-analysis supports dose de-escalation without increased immune-related adverse event risk

jitc · abstract · 2025-11-04 · 2 matching annotations

97.2%

solid tumors pembrolizumab nivolumab atezolizumab cemiplimab avelumab durvalumab docetaxel ClinicalTrials.gov N Engl J Med+1 more

…umab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult solid tumors were analyzed. Dose density (mg·kg – 1·wk– 1) was normalized by…

1071 SGLT2 inhibitor use and survival in solid tumors treated with immune checkpoint inhibitors: a real-world cohort study

jitc · abstract · 2025-11-04 · 2 matching annotations

91.3%

melanoma solid tumors lung cancer TriNetX Research Network Sodium-glucose cotransporter-2 (SGLT2) inhibitors

…p-specific estimates are shown for genitourinary, thoracic, and melanoma cohorts, with overall pooled effects labeled…

1163 A novel bispecific T cell engager for the treatment of solid tumors that express DARKFOXTM, a previously undiscovered antigen derived from an alternative open reading frame of FOXM1

jitc · abstract · 2025-11-04 · 2 matching annotations

96.3%

solid tumors ovarian carcinomas tarlatamab tebentafusp

…g in vitro and in vivo preclinical profile for the treatment of solid tumors. These TCEs exhibit robust and selective redirection of T cell …

1192 A breakthrough in fighting solid tumors with a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive tumor microenvironment

jitc · abstract · 2025-11-04 · 2 matching annotations

96.0%

solid tumors ovarian cancers APVO451

… promising anti-cancer therapeutic for the treatment of various solid tumors with suppressive TME via costimulation of APC while simultaneou…

1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies

jitc · abstract · 2025-11-04 · 2 matching annotations

97.3%

solid tumors B cell malignancies TriTCE Co-Stim CellTox TM Green MSD

…timulation, engineered to improve responses in the treatment of solid tumors. Cancer Res. 2024;84(6_Supplement):6719.…

1255 Spatial multi-omics reveals distinct functional states of tertiary lymphoid structures in non-small cell lung cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

87.9%

NSCLC solid tumors University of Pittsburgh immunotherapy

…logical assessment of TLS. We used independent patient cohorts (NSCLC, ovarian, and brain metastases) to validate our findings in mul…

1262 Selective A2aR antagonism restores antitumor immunity in adenosine-enriched tumor microenvironments

jitc · abstract · 2025-11-04 · 2 matching annotations

94.9%

solid tumors COMP-015

…istance and improve the efficacy of existing immunotherapies in solid tumors characterized by high adenosine burden.…

1279 Transforming tumor research: engineering MHCs as versatile reagents

jitc · abstract · 2025-11-04 · 2 matching annotations

99.0%

solid tumors Mol Genet Genomics

…Background When dealing with solid tumors lacking specific biomarkers, the effectiveness of adoptive T ce…

169 Impact of a Vβ6/Vβ10 targeting IL-2 fusion protein (invikafusp alfa) on the peripheral immunome, including stimulation of memory T cells with self-renewing properties, in patients with cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

96.1%

solid tumors human cancers STAR0602 invikafusp alfa START-001

…specific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1: Journal for ImmunoTherapy of Cancer. …